Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,050 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
Apperloo EM, Gorriz JL, Soler MJ, Cigarrán Guldris S, Cruzado JM, Puchades MJ, López-Martínez M, Waanders F, Laverman GD, van der Aart-van der Beek A, Hoogenberg K, van Beek AP, Verhave J, Ahmed SB, Schmieder RE, Wanner C, Cherney DZI, Jongs N, Heerspink HJL. Apperloo EM, et al. Among authors: wanner c. Nat Med. 2025 Jan;31(1):278-285. doi: 10.1038/s41591-024-03327-6. Epub 2024 Oct 25. Nat Med. 2025. PMID: 39455729 Clinical Trial.
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Cherney DZI, et al. Among authors: wanner c. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27. Lancet Diabetes Endocrinol. 2017. PMID: 28666775
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ. Chin MP, et al. Among authors: wanner c. Am J Nephrol. 2018;47(1):40-47. doi: 10.1159/000486398. Epub 2018 Jan 18. Am J Nephrol. 2018. PMID: 29402767 Free PMC article. Clinical Trial.
Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe.
Brück K, Jager KJ, Zoccali C, Bello AK, Minutolo R, Ioannou K, Verbeke F, Völzke H, Arnlöv J, Leonardis D, Ferraro PM, Brenner H, Caplin B, Kalra PA, Wanner C, Castelao AM, Gorriz JL, Hallan S, Rothenbacher D, Gibertoni D, De Nicola L, Heinze G, Van Biesen W, Stel VS; European CKD Burden Consortium. Brück K, et al. Among authors: wanner c. Kidney Int. 2018 Jun;93(6):1432-1441. doi: 10.1016/j.kint.2018.01.008. Epub 2018 Apr 12. Kidney Int. 2018. PMID: 29656901 Free article.
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators. Wanner C, et al. J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12. J Am Soc Nephrol. 2018. PMID: 30314978 Free PMC article. Clinical Trial.
Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.
Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Janka R, Uder M, Schmieder RE, Eckardt KU, Schneider MP. Scheppach JB, et al. Among authors: wanner c. Hypertension. 2018 Oct;72(4):929-936. doi: 10.1161/HYPERTENSIONAHA.118.11608. Hypertension. 2018. PMID: 30354716
Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study.
Schneider MP, Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Friedrich N, Janka R, Uder M, Schmieder RE, Eckardt KU. Schneider MP, et al. Among authors: wanner c. Kidney Int Rep. 2018 Oct 11;4(2):267-274. doi: 10.1016/j.ekir.2018.10.004. eCollection 2019 Feb. Kidney Int Rep. 2018. PMID: 30775623 Free PMC article.
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI. Mayer GJ, et al. Among authors: wanner c. Kidney Int. 2019 Aug;96(2):489-504. doi: 10.1016/j.kint.2019.02.033. Epub 2019 Mar 21. Kidney Int. 2019. PMID: 31142441 Free article. Clinical Trial.
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.
Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T. Inker LA, et al. Among authors: wanner c. J Am Soc Nephrol. 2019 Sep;30(9):1735-1745. doi: 10.1681/ASN.2019010007. Epub 2019 Jul 10. J Am Soc Nephrol. 2019. PMID: 31292197 Free PMC article.
1,050 results